Traders Buy Mednax (MD) on Weakness
Traders purchased shares of Mednax, Inc (NYSE:MD) on weakness during trading hours on Thursday. $136.25 million flowed into the stock on the tick-up and $15.62 million flowed out of the stock on the tick-down, for a money net flow of $120.63 million into the stock. Of all equities tracked, Mednax had the 10th highest net in-flow for the day. Mednax traded down ($0.39) for the day and closed at $49.79
MD has been the topic of a number of analyst reports. Citigroup lowered their target price on Mednax from $52.00 to $47.00 and set a “neutral” rating on the stock in a report on Friday, November 3rd. Jefferies Group reiterated a “hold” rating and set a $44.00 target price on shares of Mednax in a report on Friday, November 3rd. Robert W. Baird increased their target price on Mednax from $47.00 to $48.00 and gave the company a “neutral” rating in a report on Friday, November 3rd. KeyCorp upgraded Mednax from a “sector weight” rating to an “overweight” rating and set a $51.00 target price on the stock in a report on Sunday, September 17th. Finally, BidaskClub cut Mednax from a “sell” rating to a “strong sell” rating in a report on Friday, August 4th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and two have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $54.50.
The stock has a market capitalization of $4,663.10, a P/E ratio of 15.23, a price-to-earnings-growth ratio of 1.60 and a beta of 0.39. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.37 and a quick ratio of 1.37.
Mednax (NYSE:MD) last issued its quarterly earnings results on Wednesday, November 1st. The company reported $0.87 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.87. Mednax had a return on equity of 10.80% and a net margin of 7.76%. The company had revenue of $868.95 million for the quarter, compared to analyst estimates of $864.78 million. During the same quarter in the prior year, the company posted $1.09 EPS. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. sell-side analysts forecast that Mednax, Inc will post 3.1 EPS for the current year.
In other Mednax news, insider John C. Pepia sold 3,000 shares of the stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $42.85, for a total transaction of $128,550.00. Following the transaction, the insider now owns 35,569 shares of the company’s stock, valued at approximately $1,524,131.65. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Cesar L. Alvarez sold 10,668 shares of the stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $42.59, for a total value of $454,350.12. Following the transaction, the director now directly owns 44,215 shares in the company, valued at approximately $1,883,116.85. The disclosure for this sale can be found here. Corporate insiders own 2.40% of the company’s stock.
Institutional investors have recently modified their holdings of the business. Fuller & Thaler Asset Management Inc. purchased a new position in shares of Mednax in the 3rd quarter worth $103,000. Pacer Advisors Inc. raised its position in shares of Mednax by 8.1% in the 2nd quarter. Pacer Advisors Inc. now owns 1,940 shares of the company’s stock worth $117,000 after buying an additional 145 shares during the period. Commonwealth Bank of Australia raised its position in shares of Mednax by 15.3% in the 2nd quarter. Commonwealth Bank of Australia now owns 2,205 shares of the company’s stock worth $132,000 after buying an additional 293 shares during the period. Daiwa Securities Group Inc. raised its position in shares of Mednax by 20.0% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,000 shares of the company’s stock worth $181,000 after buying an additional 500 shares during the period. Finally, Denali Advisors LLC purchased a new position in shares of Mednax in the 3rd quarter worth $185,000. 98.44% of the stock is currently owned by institutional investors.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.